Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
Current Clinical Utility of Gene Expression Panels in Primary Cutaneous Melanoma.
Journal: Cancers
Published: April 24, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.
Journal: Nature communications
Published: February 02, 2026
Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic.
Journal: Research and reports in urology
Published: January 09, 2024
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.
Journal: Clinical genitourinary cancer
Published: January 04, 2022
Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
Journal: Cardiovascular and interventional radiology
Published: February 11, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.
Journal: Clinical genitourinary cancer
Published: December 17, 2020
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 18, 2020
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Journal: European urology
Published: November 04, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 15, 2020
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings.
Journal: Cancer
Published: December 23, 2019
Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").
Journal: Translational andrology and urology
Published: December 07, 2019
Last Updated: 09/26/2026